Manuela Valente, Chief People Officer of SOPHiA GENETICS SA (NASDAQ:SOPH), filed a Form 4 on August 21, 2026, disclosing the exercise of share options and the subsequent sale of ordinary shares on August 19, 2026.
Key Highlights
- Option exercise: Valente exercised 10,000 share options at an exercise price of $3.2 per share on August 19, 2026.
- Shares sold: 10,000 ordinary shares were sold at a weighted average price of $7.9439, with individual transaction prices ranging from $7.90 to $8.01, inclusive.
- Remaining direct ownership: Following the transactions, Valente directly holds 210,450 ordinary shares.
- Remaining derivative holdings: According to the filing, Valente holds an aggregate total of 554,276 derivative share options across all remaining grant tranches with varying exercise prices.
- Rule 10b5-1 plan: The filing states the transactions were made pursuant to a duly adopted trading plan under Rule 10b5-1(c).
Valente's Option Exercise and Share Disposition at SOPHiA GENETICS
According to the Form 4 filed with the SEC, Manuela Valente, serving as Chief People Officer of SOPHiA GENETICS SA, executed two linked transactions on August 19, 2026. First, she acquired 10,000 ordinary shares through the exercise of share options, coded as an "M" transaction, at an exercise price of $3.2 per share. The share options exercised were described in the filing as fully vested and exercisable, with an expiration date of January 1, 2029. The exercise price of the derivative security was reported as $0 cost to dispose of the derivative itself.
On the same date, Valente disposed of 10,000 ordinary shares in a sale coded "S," at a weighted average price of $7.9439. The filing notes that the shares were sold in multiple transactions at prices ranging from $7.90 to $8.01, inclusive, and that Valente undertakes to provide full information regarding the number of shares sold at each separate price upon written request. Both transactions were indicated as having been made pursuant to a duly adopted trading plan under Rule 10b5-1(c).
Prior to these transactions, the filing indicates Valente beneficially owned 220,450 ordinary shares on a direct basis. After the exercise and sale, her direct beneficial ownership stands at 210,450 ordinary shares. The filing was signed by Elimara Brunetto as attorney-in-fact for Manuela Valente on August 21, 2026.
What Was Disclosed
The Form 4 discloses that SOPHiA GENETICS Chief People Officer Manuela Valente exercised 10,000 fully vested share options at $3.2 and sold the resulting shares at a weighted average of $7.9439, leaving her with 210,450 ordinary shares and 554,276 remaining derivative share options.




Please wait processing your request...